Latest Ratios: P/E Ratio -89.1x · EV/EBITDA 15.8x · ROE -3.7%. (2016–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $12.9B | $11.2B | $6.0B | $7.3B | $6.0B | $13.8B | $13.5B | $10.9B | $9.9B | — | — |
| Enterprise Value | $16.4B | $14.7B | $9.9B | $12.8B | $11.5B | $19.5B | $19.2B | $12.9B | $11.9B | — | — |
| P/E Ratio → | -89.08 | — | 17.81 | — | — | — | — | 163.61 | 112.61 | — | — |
| P/S Ratio | 2.51 | 2.38 | 1.36 | 1.66 | 1.35 | 2.90 | 4.14 | 3.55 | 3.23 | — | — |
| P/B Ratio | 1.96 | 1.72 | 0.99 | 1.18 | 0.82 | 1.84 | 1.60 | 1.97 | 1.90 | — | — |
| P/FCF | 31.64 | 39.55 | 15.29 | 62.69 | 22.27 | 48.35 | — | 408.44 | 28.04 | — | — |
| P/OCF | 23.05 | 20.06 | 11.13 | 27.07 | 13.20 | 28.63 | — | 48.66 | 20.30 | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.12 | 2.22 | 2.89 | 2.60 | 4.09 | 5.86 | 4.21 | 3.88 | — | — |
| EV / EBITDA | 15.83 | 15.78 | 10.82 | 12.51 | 10.75 | 19.13 | 43.55 | 18.88 | 19.50 | — | — |
| EV / EBIT | 65.01 | — | 11.94 | — | 62.27 | — | — | 82.28 | 82.73 | — | — |
| EV / FCF | — | 51.78 | 25.06 | 109.04 | 42.75 | 68.21 | — | 484.13 | 33.70 | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 43.5% | 43.5% | 43.0% | 43.9% | 44.7% | 43.6% | 38.1% | 45.6% | 42.2% | 40.6% | 45.8% |
| Operating Margin | 5.3% | 5.3% | 5.7% | 7.4% | 8.7% | 6.4% | -2.3% | 12.0% | 10.2% | 4.9% | 9.7% |
| Net Profit Margin | -4.9% | -4.9% | 7.6% | -27.9% | -1.8% | -10.1% | -17.1% | 2.2% | 2.8% | -10.8% | -1.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -3.7% | -3.7% | 5.5% | -18.2% | -1.1% | -6.0% | -8.0% | 1.3% | 1.3% | -4.2% | -0.7% |
| ROA | -1.8% | -1.8% | 2.5% | -8.2% | -0.5% | -2.8% | -4.2% | 0.8% | 1.0% | -3.6% | -0.6% |
| ROIC | 1.9% | 1.9% | 1.7% | 2.0% | 2.2% | 1.7% | -0.5% | 3.8% | 3.2% | 1.5% | 3.1% |
| ROCE | 2.2% | 2.2% | 2.1% | 2.4% | 2.7% | 2.0% | -0.6% | 4.6% | 3.9% | 1.8% | 3.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.61 | 0.61 | 0.71 | 0.93 | 0.80 | 0.84 | 0.72 | 0.42 | 0.48 | — | — |
| Debt / EBITDA | 4.31 | 4.31 | 4.73 | 5.66 | 5.47 | 6.20 | 13.92 | 3.44 | 4.05 | — | — |
| Net Debt / Equity | — | 0.53 | 0.63 | 0.87 | 0.75 | 0.76 | 0.66 | 0.36 | 0.38 | -0.04 | -0.04 |
| Net Debt / EBITDA | 3.73 | 3.73 | 4.22 | 5.32 | 5.15 | 5.57 | 12.79 | 2.95 | 3.28 | -0.70 | -0.48 |
| Debt / FCF | — | 12.23 | 9.78 | 46.34 | 20.49 | 19.86 | — | 75.69 | 5.66 | -4.30 | -5.68 |
| Interest Coverage | -0.02 | -0.02 | 2.44 | -3.31 | 0.72 | -1.16 | -3.31 | 1.99 | 4.85 | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.17 | 2.17 | 2.44 | 2.75 | 1.93 | 1.99 | 1.65 | 2.90 | 2.58 | 3.36 | 3.15 |
| Quick Ratio | 1.08 | 1.08 | 1.25 | 1.35 | 1.02 | 1.16 | 0.89 | 1.62 | 1.55 | 1.68 | 1.73 |
| Cash Ratio | 0.34 | 0.34 | 0.36 | 0.28 | 0.20 | 0.39 | 0.24 | 0.41 | 0.49 | 0.51 | 0.42 |
| Asset Turnover | — | 0.35 | 0.35 | 0.31 | 0.28 | 0.29 | 0.19 | 0.34 | 0.34 | 0.32 | 0.36 |
| Inventory Turnover | 1.53 | 1.53 | 1.61 | 1.43 | 1.59 | 1.96 | 1.28 | 1.59 | 1.76 | 1.61 | 1.80 |
| Days Sales Outstanding | — | 72.77 | 72.85 | 83.46 | 82.91 | 78.76 | 120.09 | 105.77 | 84.43 | 76.04 | 79.01 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 5.6% | — | — | — | — | 0.6% | 0.9% | — | — |
| FCF Yield | 3.2% | 2.5% | 6.5% | 1.6% | 4.5% | 2.1% | — | 0.2% | 3.6% | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $496M | $497M | $492M | $488M | $487M | $441M | $370M | $314M | $356M | $356M |
Includes 30+ ratios · 10 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ELAN stock.
Elanco Animal Health Incorporated's current P/E ratio is -89.1x. The historical average is 98.0x.
Elanco Animal Health Incorporated's current EV/EBITDA is 15.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 18.9x.
Elanco Animal Health Incorporated's return on equity (ROE) is -3.7%. The historical average is -3.4%.
Based on historical data, Elanco Animal Health Incorporated is trading at a P/E of -89.1x. Compare with industry peers and growth rates for a complete picture.
Elanco Animal Health Incorporated has 43.5% gross margin and 5.3% operating margin.
Elanco Animal Health Incorporated's Debt/EBITDA ratio is 4.3x, indicating high leverage. A ratio above 4x may signal elevated financial risk.
Key Metrics
Top Statement Risk
Leverage and thin GAAP profitability
Metrics are mathematically derived from official filings.
Forward Multiples Imply Turnaround Pricing
Based on Elanco's reported figures, the forward P/E of 23.66 and forward EV/EBITDA of 11.27 sit well below the trailing EV/EBITDA of 16.28, suggesting the market is pricing in earnings recovery rather than current results.
The trailing P/E of -92.28 is not meaningful given negative GAAP earnings, so investors should anchor on forward and EV-based multiples instead. Relative to Zoetis at 13.88 P/E and 10.78 EV/EBITDA, Elanco trades at a premium on forward earnings, which appears to reflect expectations that the innovation pipeline will restore margin expansion. Whether that premium is justified depends on whether operating margins can move durably above the 6.4% latest-quarter level.
Gross Margin Recovers, Operating Margin Lags
As reported in quarterly statements, gross margin recovered to 56.9% in 2026Q3 from 38.1% in 2024Q4, yet operating margin of 6.4% and net margin of 1.4% indicate that gains have not yet flowed through to bottom-line earnings.
The gap between gross and operating margin suggests a heavy fixed cost base in sales and manufacturing absorbing most of the gross profit recovery. The sharp swings in net margin, including a 35.3% print in 2024Q3, point to non-operating items distorting reported earnings, so operating margin is the more reliable read on earning power. Investors should monitor whether the operating margin can sustain above 8% across consecutive quarters before concluding the margin recovery is structural.
Deleveraging Progress Remains Fragile
Based on Elanco's reported figures, debt-to-equity fell from 0.96 in 2024Q2 to 0.56 in 2026Q3, but EBITDA-based leverage of 44.66x in the latest quarter and interest coverage of 1.41x indicate debt service remains tight.
The D/E improvement is real but partly reflects equity base dynamics, and the quarterly D/EBITDA swings from 8.33x to 44.66x show that earnings volatility, not just debt levels, drives the leverage picture. Interest coverage near 1.4x leaves limited room for an earnings shortfall before debt service becomes a constraint. Investors should watch whether leverage ratios stabilize as quarterly EBITDA normalizes, since the current figures may understate or overstate underlying debt burden.
Current Ratio Adequate, Cash Buffer Thin
According to reported balance sheet data, the current ratio of 2.09 and quick ratio of 1.07 indicate near-term obligations are covered, though cash of $465.0M equals only about 3.5% of total assets.
The quick ratio remaining above 1.0 suggests the liquidity position does not depend heavily on inventory conversion, which is a relative strength in a business carrying substantial manufacturing inventory. However, the low cash share of assets implies limited buffer against a sudden operating shock or a delay in receivables collection. Under severe stress, the position would likely depend on continued working capital inflows that have proven volatile across recent quarters.
Cash Strength May Reflect Timing Effects
Based on reported quarterly figures, operating cash flow of $216.0M in 2026Q3 against net income of $18.0M appears strong, but the recent working capital swing of $239.0M suggests much of the cash conversion may be timing-driven rather than durable.
A 12x cash conversion ratio is unusual and warrants scrutiny, since large working capital releases can flatter a single quarter without reflecting sustainable economics. The DSO of 81 days alongside DPO of 71 days and a cash conversion cycle of 312 days suggests working capital is tied up for long periods, so any reversal in payables timing could reverse recent cash gains. Investors should treat the free cash flow margin of 12.3% as provisional until several quarters show consistent conversion.